GENELUX CORPORATION’S LEADERSHIP IN ONCOLYTIC VIROTHERAPY

Genelux is leading the way in understanding and translating the science behind oncolytic viruses. We have developed a robust drug discovery capability, and are building a pipeline of innovative oncolytic virus-based cancer therapies and collaborates with leading medical and academic research institutions, clinicians and scientists to replicate, validate, and maximize the potential applications and impact of its discoveries.

Our record of scientific leadership in oncolytic virotherapy demonstrates the potential of novel oncolytic viruses, and our commitment to advancing this promising therapeutic approach for the benefit of cancer patients worldwide.